Capricor Therapeutics (CAPR) News Today

Capricor Therapeutics, Inc. (NASDAQ: CAPR) saw its stock price decrease amid a flurry of class action lawsuit filings and downward revisions to its earnings forecasts by research analysts.

• Neutral Sentiment: Cantor Fitzgerald cut its FY2025 EPS estimate for CAPR to ($1.98) from ($1.71) but maintained an “Overweight” rating and a $30.00 price target. Research Analysts Set Expectations for CAPR FY2025 Earnings
• Neutral Sentiment: Roth Capital reduced its Q3 2025 EPS forecast for CAPR to ($0.44) from $1.28 but kept a “Buy” rating and a $12.00 target. What is Roth Capital's Forecast for CAPR Q3 Earnings?
• Neutral Sentiment: MMM Online’s “Rx Rundown” covered industry peers including Sarepta, Juul and Pfizer; Capricor was mentioned in broader biotech coverage. Rx Rundown: Sarepta Therapeutics, Juul, Pfizer and more
• Neutral Sentiment: BioSpace report on FDA decision-making referenced Moderna’s pediatric COVID shot but did not directly affect Capricor’s programs. Vinay Prasad Overruled Reviewers on Moderna’s COVID-19 Shot for Kids
• Negative Sentiment: Bronstein, Gewirtz & Grossman LLC filed a class action on behalf of Capricor investors with substantial losses against the company and certain officers. CAPR INVESTOR ALERT
• Negative Sentiment: Faruqi & Faruqi, LLP is investigating claims for investors who suffered losses exceeding $50,000 in Capricor securities. DEADLINE ALERT
• Negative Sentiment: Bernstein Liebhard LLP issued an alert for investors with large losses to discuss their rights in a class action against Capricor. Investor Alert
• Negative Sentiment: Gainey McKenna & Egleston filed a securities class action for purchasers of Capricor shares between October 2024 and July 2025. Class Action Lawsuit Filed
• Negative Sentiment: The Schall Law Firm announced investors can lead a securities fraud lawsuit against Capricor. Schall Law Firm Alert
• Negative Sentiment: Robbins LLP informed shareholders of a class action covering Capricor securities acquired from October 2024 through July 2025. Shareholder Alert
• Negative Sentiment: Holzer & Holzer, LLC filed a class action alleging misleading statements about Phase 2 HOPE-2 trial data. Investor Alert
• Negative Sentiment: Levi & Korsinsky, LLP notified investors of a complaint and set a lead plaintiff deadline of September 15, 2025, for Capricor purchasers. Shareholder Alert
• Negative Sentiment: Block & Leviton announced a securities fraud lawsuit against Capricor, urging investors to contact the firm. Breaking: Securities Fraud Suit
• Negative Sentiment: Pomerantz LLP is investigating claims on behalf of Capricor investors who may have been misled, advising them to get in touch. Investor Alert